Wyeth Q2 2008 Earnings Call Transcript (at Seeking Alpha)

                   
yahoo.com     Jul 23, 2008            

posted on: July 23, 2008 | about stocks: WYE Executives Gregory Norden - Sr. VP and CFO Bernard Poussot - Chairman, President and CEO Joseph M. Mahady - Sr. VP Justin R. Victoria - VP, IR Analysts Catherine Arnold - Credit Suisse Anthony Butler - Lehman Brothers Tim Anderson - Sanford Bernstein David Risinger - Merrill Lynch Roopesh Patel - UBS Seamus Fernandez - Leerink Swann John Boris - Citigroup Stephen Scala - Cowen and Company James Kelly - Goldman Sachs Chris Schott - JPMorgan Operator Ladies and gentlemen, thank you for standing by and welcome to the Wyeth Second Quarter Earnings Conference Call. At this time, all lines are in a listen-only mode. Later, there will be a question-and-answer session, and instructions will be given at that time. [Operator Instructions]. As a reminder, today's call is being recorded. At... [read full story]                    

FULL COVERAGE

Earnings Preview: Wyeth (at Seeking Alpha)

yahoo.com     Jul 22, 2008          

by: theflyonthewall.com posted on: July 22, 2008 | about stocks: TEVA / WYE ) is expected to report Q2 earnings before market open Wednesday, July 23, with a conference call scheduled for 8:00 am ET. Guidance Analysts are...                    

comments

                   

Flat earnings seen for drugmaker Wyeth (AP)

yahoo.com     Jul 23, 2008          

Tuesday July 22, 6:01 pm ET Flat earnings, unimpressive sales seen for drugmaker Wyeth due to generic competition MADISON, N.J. (AP) -- OVERVIEW: Wyeth had been benefiting from a diverse product mix, with seven drugs or...                    

comments

                   

Flat earnings seen for drugmaker Wyeth

ibtimes.com     Jul 23, 2008          

MADISON, N.J. - OVERVIEW: Wyeth had been benefiting from a diverse product mix, with seven drugs or vaccines each producing annual sales of $1 billion or more, until No. 4 seller Protonix, for severe heartburn, got generic...                    

comments

                   

Earnings Preview: Wyeth 2Q profits seen flat (AP)

yahoo.com     Jul 23, 2008          

Tuesday July 22, 7:50 pm ET Flat earnings, unimpressive sales seen for drugmaker Wyeth due to generic competition MADISON, N.J. (AP) -- OVERVIEW: Wyeth had been benefiting from a diverse product mix, with seven drugs or...                    

comments

                   

Earnings Preview: Wyeth 2Q profits seen flat

ibtimes.com     Jul 23, 2008          

MADISON, N.J. - OVERVIEW: Wyeth had been benefiting from a diverse product mix, with seven drugs or vaccines each producing annual sales of $1 billion or more, until No. 4 seller Protonix, for severe heartburn, got generic...                    

comments

                   

Flat earnings seen for drugmaker Wyeth

drugpolicycentral.com     Jul 23, 2008          

During the second quarter, Wyeth got FDA approval for Relistor, a shot to treat opioid-induced constipation, but the agency again held up approval of osteoporosis treatment Viviant, requiring more information on strokes and...                    

comments

                   

Earnings Preview: Wyeth 2Q profits seen flat

drugpolicycentral.com     Jul 23, 2008          

During the second quarter, Wyeth got FDA approval for Relistor, a shot to treat opioid-induced constipation, but the agency again held up approval of osteoporosis treatment Viviant, requiring more information on strokes and...                    

comments

Wyeth profit crimped by generic competition, restructuring

marketwatch.com     Jul 23, 2008          

By Val Brickates Kennedy, MarketWatch Wyeth profit hit by generic competition, restructuring BOSTON (MarketWatch) -- Wyeth reported modestly lower second-quarter earnings early Wednesday, due in part to restructuring costs and...                    

comments

Wyeth profit crimped by generic competition, restructuring (at MarketWatch)

yahoo.com     Jul 23, 2008          

By Val Brickates Kennedy, MarketWatch Wyeth profit hit by generic competition, restructuring BOSTON (MarketWatch) -- Wyeth reported modestly lower second-quarter earnings early Wednesday, due in part to restructuring costs and...                    

comments

Biotech Stocks: Drug stocks inch up; Wyeth climbs on financial forecast (at MarketWatch)

yahoo.com     Jul 23, 2008          

Drug stocks inch up, with Wyeth climbing on forecast By Val Brickates Kennedy, MarketWatch BOSTON (MarketWatch) -- Drug stocks edged higher early Wednesday as shares of Wyeth gained after it raised its 2008 financial forecast....                    

comments

1 2 3 next